Bibliography
- Couri CE , OliveiraMC, StracieriABet al.: C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus.JAMA301 , 1573–1579 (2009).
- Voltarelli JC , CouriCE, StracieriABet al.: Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus.JAMA297 , 1568–1576 (2007).
- Huurman VA , HilbrandsR, PinkseGGet al.: Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation.PLoS One3 , E2435 (2008).
- Sutherland DE , SibleyR, XuXZet al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of Type I diabetes. Trans. Assoc. Am. Physicians 97 , 80–87 (1984).
- Cure P , PileggiA, FroudTet al.: Alterations of the female reproductive system in recipients of islet grafts.Transplantation78 , 1576–1581 (2004).
- Bresson D , TogherL, RodrigoEet al.: Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.J. Clin. Invest.116 , 1371–1381 (2006).
- Chatenoud L , ThervetE, PrimoJ, BachJF: Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.Proc. Natl Acad. Sci. USA91 , 123–127 (1994).
- Alleva DG , MakiRA, PutnamALet al.: Immunomodulation in Type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.Scand. J. Immunol.63 , 59–69 (2006).
- Herold KC , GitelmanSE, MasharaniUet al.: A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala–Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes.Diabetes54 , 1763–1769 (2005).
- Herold KC , HagopianW, AugerJAet al.: Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus.N. Engl. J. Med.346 , 1692–1698 (2002).
- Keymeulen B , VandemeulebrouckeE, ZieglerAGet al.: Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes.N. Engl. J. Med.352 , 2598–2608 (2005).
- Pescovitz MD , GreenbaumCJ, Krause-SteinraufHet al.: Rituximab, B-lymphocyte depletion, and preservation of β-cell function.N. Engl. J. Med.361 , 2143–2152 (2009).
- Ludvigsson J , FaresjoM, HjorthMet al.: GAD treatment and insulin secretion in recent-onset Type 1 diabetes.N. Engl. J. Med.359 , 1909–1920 (2008).
- Thrower SL , JamesL, HallWet al.: Proinsulin peptide immunotherapy in Type 1 diabetes: report of a first-in-man Phase I safety study.Clin. Exp. Immunol.155 , 156–165 (2009).
- Bresson D , FradkinM, ManenkovaY, RottembourgD, von Herrath M: Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset Type 1 diabetes. Mol. Ther.18 , 307–316 (2010).
- Sherry NA , ChenW, KushnerJAet al.: Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of β-cells.Endocrinology148 , 5136–5144 (2007).
- Palmer AJ , ValentineWJ, RayJAet al.: An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with Type 1 diabetes in the UK.Curr. Med. Res. Opin.23 , 895–901 (2007).
- Filippi CM , von Herrath MG: 99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: viruses, autoimmunity and immunoregulation. Clin. Exper. Immunol.160(1) , 113–119 (2010).
▪ Website
- Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf